ABIVAX (EPA:ABVX) | Finanzwire

Basculer en Français

9535	Companies
187704	Keywords
119664	Articles
100297	Press releases

Home
Companies
ABIVAX

BRIEF

published on 12/15/2025 at 22:10, 15 hours 3 minutes ago

Abivax: Third Quarter 2025 Financial Results

Financial Results Treasury Abivax Net Loss R&D Expenditures
BRIEF

published on 12/15/2025 at 22:10, 15 hours 3 minutes ago

Abivax Reports Third Quarter 2025 Financial Results

Cash Position Biotech Funding R&D Expenses Q3 2025 Results Abivax Financials
PRESS RELEASE

published on 12/15/2025 at 22:05, 15 hours 8 minutes ago

Abivax Presents Third Quarter 2025 Financial Results
Abivax presents its third quarter 2025 financial results with EUR 589.7 cash and cash equivalents, providing key updates on its business and operational goals

Financial Results Abivax Third Quarter Operational Goals Cash Equivalents
BRIEF

published on 12/12/2025 at 18:05, 3 days 19 hours ago

ABIVAX: Publication of Capital and Voting Rights Data as of November 30, 2025

Financial Information Share Capital Voting Rights Abivax AMF Regulations
BRIEF

published on 11/19/2025 at 18:05, 26 days 19 hours ago

ABIVAX: Information on share capital and voting rights as of October 31, 2025

Euronext Paris Share Capital Voting Rights AMF Abivax
BRIEF

published on 11/19/2025 at 18:05, 26 days 19 hours ago

ABIVAX: Share and voting rights balance sheet as of October 31, 2025

Share Capital Voting Rights Biotechnology Actions Abivax
BRIEF

published on 11/03/2025 at 22:10, 1 month 12 days ago

Abivax reveals promising results for Obefazimod in the treatment of ulcerative colitis

Abivax Obefazimod Ulcerative Colitis Phase 3 Trials Clinical Results
PRESS RELEASE

published on 11/03/2025 at 22:05, 1 month 12 days ago

Abivax Announces Patient-Reported Outcomes Data from the Phase 3 ABTECT Induction Trials of Obefazimod, Demonstrating Significant Improvements in Quality of Life for Patients with Ulcerative Colitis
Abivax announces significant improvements in quality of life for patients with ulcerative colitis in Phase 3 ABTECT induction trials of Obefazimod, incorporating patient-reported outcomes data

Abivax Obefazimod Ulcerative Colitis Phase 3 Patient-reported Outcomes
BRIEF

published on 10/24/2025 at 09:41, 1 month 23 days ago

JP Morgan Chase & Co. Crosses the 5% Threshold at ABIVAX

Voting Rights Capital Abivax Crossing Thresholds JP Morgan
BRIEF

published on 10/15/2025 at 18:05, 2 months ago

ABIVAX: Status of shares and voting rights as of September 30, 2025

Share Capital Voting Rights Biotechnology Euronext Abivax

Accesswire

Published on 12/16/2025 at 13:00, 13 minutes ago

Abasca Resources Provides Exploration Update at its Loki Flake Graphite Deposit and Granting Stock Option
Published on 12/16/2025 at 13:00, 13 minutes ago

Silver Wolf Completes Acquisition of the Ana Maria Project
Published on 12/16/2025 at 12:00, 1 hour 13 minutes ago

Tokenwell Plans to Establish U.S. Subsidiary in Dallas, Texas, to Expand its Presence in the Growing Digital Asset Hub
Published on 12/16/2025 at 12:00, 1 hour 13 minutes ago

CTT Pharma's Scientists Publish Peer-Reviewed Paper in the Journal of Drug Delivery and Therapeutics
Published on 12/16/2025 at 12:00, 1 hour 13 minutes ago

Snowline Gold Awards Key Contracts and Commences Prefeasibility Study on its Flagship Rogue Project, Yukon

View all ACCESSWIRE

EQS Group

Published on 12/16/2025 at 12:55, 18 minutes ago

Banyan Group's Garrya Mu Cang Chai Opens in a National Heritage Site in Northern Vietnam
Published on 12/16/2025 at 12:22, 51 minutes ago

REPLOID Group AG: HEROSAN launches crowdfunding campaign
Published on 12/16/2025 at 12:05, 1 hour 8 minutes ago

BRP Announces Appointment of Denis Le Vot as President and Chief Executive Officer
Published on 12/16/2025 at 12:00, 1 hour 13 minutes ago

DATAGROUP initiates delisting procedure on the Munich Stock Exchange
Published on 12/16/2025 at 11:49, 1 hour 24 minutes ago

Strategic Investment: CANSOUL acquires stake in SYNBIOTIC

Les Echos

Published on 12/16/2025 at 08:30, 4 hours 43 minutes ago

Cie du Bois Sauvage: Buy back of own shares – week from 08/12/2025 to 12/12/2025
Published on 12/15/2025 at 22:36, 14 hours 37 minutes ago

Disclosure of trading in own shares between December 1st and December 5th, 2025
Published on 12/15/2025 at 18:30, 18 hours 43 minutes ago

MCH PRIVATE EQUITY AND EURAZEO ENTER INTO AN EXCLUSIVE AGREEMENT WITH ARDIAN FOR THE SALE OF THEIR MAJORITY STAKE IN FERMAX
Published on 12/15/2025 at 18:05, 19 hours 8 minutes ago

Covivio - Treasury shares transactions between December 8th , 2025 and December 12th, 2025
Published on 12/15/2025 at 17:45, 19 hours 28 minutes ago

ENGIE strengthens the resilience of the Belgian electricity system with new flexible capacities

View all LES ECHOS COMFI WIRE